Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 25 versus FENTANYL CITRATE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 25 versus FENTANYL CITRATE PRESERVATIVE FREE.
FENTANYL-25 vs FENTANYL CITRATE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia by activating G-protein coupled opioid receptors in the CNS, leading to decreased neurotransmitter release and hyperpolarization of neurons.
Synthetic opioid agonist; primarily binds to mu-opioid receptors in the CNS, modulating nociceptive pathways and producing analgesia, sedation, and euphoria.
25 mcg/h transdermal patch applied every 72 hours; for opioid-tolerant patients only.
Initial: 50-100 mcg IV every 2-5 minutes as needed for pain. For anesthesia: 2-50 mcg/kg IV bolus, then 0.7-10 mcg/kg/hr infusion.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 3-12 hours in elderly, hepatic impairment, or critical illness; context: duration of action shorter due to redistribution.
Terminal elimination half-life is approximately 2–4 hours in healthy adults, but may be prolonged to 4–12 hours in elderly, critically ill, or obese patients due to increased volume of distribution and decreased clearance. Context: Duration of action after a single bolus is relatively short due to redistribution, but accumulation can occur with repeated doses or infusions, leading to prolonged effects.
Renal (75% as metabolites, <10% unchanged); Fecal (9%); Biliary (minor).
Primarily hepatic metabolism via CYP3A4, with approximately 75% of the dose excreted in urine as metabolites (primarily norfentanyl) and <10% as unchanged fentanyl. About 9% is excreted in feces. Minimal biliary excretion.
Category D/X
Category D/X
Opioid Agonist
Opioid Agonist